The principal U.S. patents covering BlueWillow’s proprietary NanoVax™ adjuvant technology platform have been granted. This effectively protects the company’s mucosal vaccine formulations and applications.
BlueWillow’s technology is both broadly and narrowly protected by composition and method claims reflected in 20+ issued U.S. patents and 30+ issued international patents, as well as numerous pending CIP and new patent filings. The issued U.S. patents provide protection up through 2030 and beyond for the company’s key intranasal vaccine candidates.
BlueWillow’s patent counsel is Foley & Lardner, LLP, located in Washington, DC.